-
Immunochemical fecal occult blood testing (i-FOBT) is becoming increasingly popular as a screening tool for colorectal cancer (CRC).
-
Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
-
IRBs should work to create balanced IRB discussions and ensure cooperation between members of diverse backgrounds.
-
IRBs can learn a great deal from each other. One research institution's hard-earned lesson and resolution can be another organization's best practices.
-
When and how to release biomarker results is complicated issue for researchers, IRBs
-
The Office for Human Research Protections (OHRP) has posted its updated and finalized guidance on the IRB continuing review process.
-
IRBs often do a good, or at least adequate, job of maintaining required documentation for studies they review, but there are several key documentation areas in which many IRBs need to improve, according to experts.
-
When a group of researchers set out to study effective ways to screen HMO members for substance abuse problems and to refer them for treatment, they expected that sensitive topic would require strict confidentiality measures.
-
Patients hospitalized with depression may need extra help understanding the informed consent process for research, due to cognitive impairments that affect their ability to understand information being given to them about a study.
